Chinese vaccine 'successful in mid-stage trials'
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Saturday
January 28, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
SATURDAY, JANUARY 28, 2023
Chinese vaccine 'successful in mid-stage trials'

World+Biz

TBS Report
18 November, 2020, 04:05 pm
Last modified: 18 November, 2020, 04:24 pm

Related News

  • Pakistan approves Chinese Sinopharm Covid-19 vaccine for emergency use
  • Wariness in Indonesia as Chinese Sinovac Covid-19 jabs start
  • Malaysia's Pharmaniaga buys 14m doses of China's Sinovac Covid vaccine
  • Brazil health regulator says application for Sinovac vaccine lacks information
  • Not allowing the Chinese vaccine was the wrong decision: Prof Nazrul

Chinese vaccine 'successful in mid-stage trials'

A Covid-19 vaccine developed in China has shown success in mid-stage trials, according to the researchers

TBS Report
18 November, 2020, 04:05 pm
Last modified: 18 November, 2020, 04:24 pm
The question arises whether a member state would want to administer to its citizens a vaccine that has not been reviewed by EMA

Photo: Collected
The question arises whether a member state would want to administer to its citizens a vaccine that has not been reviewed by EMA Photo: Collected

China is racing to develop a Covid vaccine like the rest of the world and four have entered the third and final stage of clinical trials, including the one created by Sinovac Biotech. According to the researchers, the vaccine led to a quick immune response during trials with around 700 people. 

However, the results published in the scientific journal The Lancet are only from the first and second trial phases of one of those four vaccines. According to the report, Sinovac Biotech's CoronaVac triggered a quick immune response, although the study conducted in April and May this year did not give a percentage of the vaccine's success rate.

Zhu Fengcai, one of the paper's authors, said the results - which are based on 144 participants in the phase 1 trial and 600 in the phase 2 trial - meant the vaccine was "suitable for emergency use". No data from the ongoing large-scale phase 3 trials has been published yet.

With the pandemic reported to be almost entirely under control within China, late-stage trials of the four Chinese vaccines are being conducted in Pakistan, Saudi Arabia, Russia, Indonesia and Brazil. According to officials, nearly 60,000 people had received a vaccine by early November.

Trials of the Sinovac Biotech vaccine in Brazil were briefly halted last week but resumed after the reported death of a volunteer was found to have no links to the vaccine. At least three of the vaccines are also already being offered to essential workers as part of an emergency programme, while one was approved for the Chinese military in June.

Following the announcement of not one but two successful potential vaccines for coronavirus in the space of a week, attention is understandably focused on the minutiae of the latest developments. Under normal circumstances, the results of phase 1 and phase 2 trials of a drug would not raise an eyebrow outside the lab. These stages are largely to check if the pharmaceutical is safe and might be effective to try out in more expensive-to-run phase 3 trials. This is what Sinovac has announced.

Its vaccine is different from the ones announced by Pfizer/BionTech and Moderna in that it has been developed using more traditional methods. It uses a chemically inactivated version of the virus. The manufacturers highlight the fact that their vaccine gives a "quick" response in the trials - developing virus-fighting antibodies within 14 days of receiving a dose. This feature would make it suitable for emergency use, they say, during an outbreak or for healthcare workers.

All promising stuff, but we should wait to see the results of the larger scale trials currently underway in Brazil, Indonesia and Turkey before drawing any firm conclusions about its effectiveness. And even then, just like the phase 3 results that have been and will soon be announced, they should be taken in with a healthy dose of caution. Researchers won't know how effective any of them will be in the long term until they start being rolled out in the general population.

The development of vaccines does not mark the end of the pandemic, but the beginning of a long and slow return to normality.

How does it compare with the other vaccines?

Over the past few days, there has been a string of promising vaccine news from around the world.

First, a German-US vaccine by Pfizer and BioNtech was reported to be more than 90% effective based on late-stage trials with more than 43,000 people

Then, US company Moderna said its vaccine showed nearly 95% efficiency, also after large late-stage trials. In both cases the results are preliminary and both vaccines have not yet been approved.

And a Russian Covid vaccine was reported to be 92% effective after trials with 16,000 volunteers. It was already granted approval for emergency use within Russia in August.

Researchers behind all three of those vaccines have released data from more advanced testing stages than the Chinese vaccine. But Sinovac Biotech is conducting these same late-stage trials as well, and the fact that there is no data released on those trials does not necessarily mean that the other researchers are ahead.

The use of the vaccine candidates for emergency cases in China - like medical frontline staff - suggests authorities have a certain level of trust in the jabs.

Which of those vaccines will be first rolled out on a large scale still remains to be seen. Approval and mass production would be the next hurdles and experts caution not to expect widespread vaccination programmes before next year.

Top News

Sinovac Biotech

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • How will Bangladesh pay for massive upcoming power projects this year?
    How will Bangladesh pay for massive upcoming power projects this year?
  • Photo: Mumit M/TBS
    Additional Tk2,682cr sought for Padma Bridge project
  • Now is the time to focus on FDI composition
    Now is the time to focus on FDI composition

MOST VIEWED

  • A woman on a mobility scooter drives past a mural praising the NHS (National Health Service) amidst the continuation of the coronavirus disease (COVID-19) pandemic, London, Britain, March 5, 2021. REUTERS/Toby Melville/File Photo
    Hundreds of thousands of UK healthcare workers balloted for strikes
  • Adani Group Chairman Gautam Adani in a 2009 photo. Photo: Collected
    India's Gautam Adani: Asia's richest man in the eye of a storm
  • Chief Executive of oil producer Rosneft Igor Sechin attends a meeting with Russian President Vladimir Putin at the Novo-Ogaryovo state residence outside Moscow, Russia February 15, 2021. Sputnik/Mikhail Klimentyev/Kremlin via REUTERS/File Photo
    Russia's Sechin says Taiwan will return to China 'on schedule'
  • Elon Musk attends the opening ceremony of the new Tesla Gigafactory for electric cars in Gruenheide, Germany, March 22, 2022. Patrick Pleul/Pool via REUTERS/File Photo
    Elon Musk, White House discuss electric vehicles
  • China's and U.S.' flags are seen printed on paper in this illustration taken January 27, 2022. REUTERS/Dado Ruvic/Illustration/File Photo
    China says willing to communicate with US military but 'red lines' should be respected
  • Photo: Collected
    2 dead, 2 missing as rain pounds New Zealand's largest city

Related News

  • Pakistan approves Chinese Sinopharm Covid-19 vaccine for emergency use
  • Wariness in Indonesia as Chinese Sinovac Covid-19 jabs start
  • Malaysia's Pharmaniaga buys 14m doses of China's Sinovac Covid vaccine
  • Brazil health regulator says application for Sinovac vaccine lacks information
  • Not allowing the Chinese vaccine was the wrong decision: Prof Nazrul

Features

Now is the time to focus on FDI composition

Now is the time to focus on FDI composition

1h | Panorama
Sketch:TBS

Why we need consumer education for consumer wellbeing

21h | Thoughts
Dr Ahsan H Mansur, Executive Director, Policy Research Institute. Illustration: TBS

Twin shocks call for stronger domestic policy response

22h | Thoughts
December-er shohor, taxi taken for airport and the Park Street bathed in lights. Photo: Jannatul Naym Pieal

Exploring Kolkata on foot, empowered by Google Maps

23h | Explorer

More Videos from TBS

Kajol’s road paintings bring change in Gafargaon

Kajol’s road paintings bring change in Gafargaon

1d | TBS Stories
Carew & Company witnessed a remarkable growth

Carew & Company witnessed a remarkable growth

1d | TBS Stories
Gavi may have to leave Camp Nou

Gavi may have to leave Camp Nou

12h | TBS SPORTS
After all the controversies, how is Shah Rukh Khan's ‘Pathaan’?

After all the controversies, how is Shah Rukh Khan's ‘Pathaan’?

14h | TBS Entertainment

Most Read

1
Picture: Collected
Bangladesh

US Embassy condemns recent incidents of visa fraud

2
Four top bankers arrested in DSA case filed by S Alam group 
Bangladesh

Four top bankers arrested in DSA case filed by S Alam group 

3
Illustration: TBS
Banking

16 banks at risk of capital shortfall if top 3 borrowers default

4
Photo: Collected
Splash

Hansal Mehta responds as Twitter user calls him 'shameless' for making Faraaz

5
A frozen Beyond Burger plant-based patty. Photographer: AKIRA for Bloomberg Businessweek
Bloomberg Special

Fake meat was supposed to save the world. It became just another fad

6
Representational Image
Banking

Cash-strapped Islami, Al-Arafah and National turn to Sonali Bank for costly fund

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]